Adherence to fremanezumab and reduction of analgesic intake in patients with migraine
Clinical review for general practice · 15.10.2026 · 7 (8) · 20-26
DOI: 10.47407/kr2026.7.8.00895 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical review for general practice, online erschienen am 15.10.2026. Verfasst von Anna Yu Timokhovich und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Migraine ranks second worldwide in terms of lost workdays, according to the World Health Organization. A key aspect of treatment is following recommended preventive therapy regimens and assessing how preventive therapy affects the frequency of using medications to relieve migraine attacks.
Objective
To study adherence to fremanezumab treatment and the factors influencing it, as well as the dynamics of analgesics intake in the course of fremanezumab therapy. Materials and methods. The study included 80 patients diagnosed with migraine and depression. Patients received monthly subcutaneous fremanezumab 225 mg injections for at least 6 months. After the study period, patients could continue therapy and provide headache diaries during follow-up. Treatment adherence was measured by the proportion of days covered (PDC) and medication possession ratio. PDC was defined as the number of days covered by fremanezumab divided by a fixed follow-up period of 6months.
Results
Adherence to fremanezumab treatment in our study was high: the average PDC score was 98.3% in the first 6 months of observation. This could be due to monthly visits, during which patients could discuss their current issues, learn about attack management rules, and receive support and reassurance. However, treatment adherence remained high even after 6 months of treatment (92.1%). A statistically significant reduction in analgesic use was observed during fremanezumab therapy starting at the second month of treatment and continued throughout the entire treatment period.
Conclusion
Fremanezumab therapy is highly effective. It reduces the number of headache days and the use of analgesics, demonstrates high patient adherence and good tolerability. Keywords: migraine, monoclonal antibodies, fremanezumab, calcitonin gene-related peptide.
Zitieren
APA
Timokhovich, A. Y., Latysheva, N. V., & Latysheva, N. V. (2026). Adherence to fremanezumab and reduction of analgesic intake in patients with migraine. Clinical review for general practice, 7(8), 20-26. https://doi.org/10.47407/kr2026.7.8.00895
Vancouver
Timokhovich AY, Latysheva NV, Latysheva NV. Adherence to fremanezumab and reduction of analgesic intake in patients with migraine. Clinical review for general practice. 2026;7(8):20-26. doi:10.47407/kr2026.7.8.00895
BibTeX
@article{Timokhovich2026,
author = {Timokhovich, Anna Yu and Latysheva, Nina V and Latysheva, Nina V},
title = {Adherence to fremanezumab and reduction of analgesic intake in patients with migraine},
journal = {Clinical review for general practice},
year = {2026},
volume = {7},
number = {8},
pages = {20--26},
doi = {10.47407/kr2026.7.8.00895}
}
EUVIMED